Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
Follow-Up Questions
Who is the CEO of Traws Pharma Inc?
Dr. Werner Cautreels is the Chief Executive Officer of Traws Pharma Inc, joining the firm since 2024.
What is the price performance of TRAW stock?
The current price of TRAW is $2.81, it has decreased 1.71% in the last trading day.
What are the primary business themes or industries for Traws Pharma Inc?
Traws Pharma Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Traws Pharma Inc market cap?
Traws Pharma Inc's current market cap is $19.8M
Is Traws Pharma Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Traws Pharma Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
